Your browser doesn't support javascript.
loading
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Mezynski, J; Pezaro, C; Bianchini, D; Zivi, A; Sandhu, S; Thompson, E; Hunt, J; Sheridan, E; Baikady, B; Sarvadikar, A; Maier, G; Reid, A H M; Mulick Cassidy, A; Olmos, D; Attard, G; de Bono, J.
Afiliação
  • Mezynski J; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Pezaro C; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Bianchini D; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Zivi A; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Sandhu S; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Thompson E; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Hunt J; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Sheridan E; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Baikady B; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Sarvadikar A; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Maier G; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Reid AHM; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Mulick Cassidy A; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Olmos D; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
  • Attard G; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address: Gerhardt.attard@icr.ac.uk.
  • de Bono J; Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
Ann Oncol ; 23(11): 2943-2947, 2012 Nov.
Article em En | MEDLINE | ID: mdl-22771826
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Prevencao_e_fatores_de_risco / Agentes_cancerigenos / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Taxoides / Androstenóis / Antineoplásicos Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2012 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Prevencao_e_fatores_de_risco / Agentes_cancerigenos / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Taxoides / Androstenóis / Antineoplásicos Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2012 Tipo de documento: Article País de afiliação: Reino Unido